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Abstract   
Background: Atrial fibrillation (AF) is common among people with stroke. Anticoagulation 
medications can be used to manage the deleterious impact of AF after stroke, however may not 
be prescribed due to concerns about post-stroke falls and decreased functioning. Thus, the 
purpose of this study was to identify, among people with stroke and AF, predictors of 
anticoagulation prescription at hospital discharge. 
 
Methods: This is a secondary analysis of a retrospective cohort study of data retrieved via 
medical records, including: National Institutes of Health Stroke Scale score; Functional 
Independence Measure (FIM) motor score (motor or physical function); ambulation on 2nd day of 
hospitalization; Morse Falls Scale (fall risk); and HAS-BLED score (Hypertension; Abnormal 
renal and liver function; Stroke; Bleeding; Labile INRs; Elderly > 65; and Drugs or alcohol). Data 
analyses included bivariate comparisons between people with and without anticoagulation at 
discharge. Logistic-regression modeling was used to assess predictors of discharge anti-
coagulation.  
 
Results: There were 334 subjects included in the analyses, average age was 75 years old. 
Anticoagulation was prescribed at discharge for 235 (70%) of patients. In the adjusted 
regression analyses, only the FIM motor score (adjusted OR = 1.015, 95%CI 1.001-1.028) and 
the HAS-BLED score (adjusted OR = 0.36, 95%CI 0.22-0.58) were significantly associated with 
anticoagulation prescription at discharge.  
 
Conclusion: It appears that in this sample, post-stroke anti-coagulation decisions appear to be 
made based on clinical factors associated with bleed risk and motor deficits or physical 
functioning.  However, opportunities may exist for improving clinician documentation of specific 
reasoning for non-anticoagulation prescription. 
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Introduction 
Atrial fibrillation (AF) is a major modifiable risk factor for stroke. Annually, 60,000 strokes 
occur in the 2.3 million Americans who have atrial AF,1 an important and serious combination 
that should be addressed.2, 3 AF, and subsequent stroke risk, can be mitigated with the use of 
anticoagulation medications. Such medications can reduce the risk of stroke by two thirds, but 
these medications also increase the risk of future bleeding.3, 4 Guidelines for the management of 
patients with AF indicate that the appropriate choice of treatment should be guided by the 
relative risk of stroke and bleeding.5 The net benefit of anticoagulation for AF has been shown 
to be greatest among patients with a history of stroke.6 Having a stroke places patients at 
intermediate or high risk for future thromboembolic events, thus stroke patients are likely to 
benefit the most from anticoagulation medications.6, 7  
A potential barrier to the use of anticoagulation, especially among the elderly or those 
with impaired physical functioning, is the concern about fall risk. Patients with stroke are at 
increased risk for falls, with up to 73% falling in the first six-months after stroke.8 Falls remain 
common in the chronic post-stroke period9 and are linked to injuries and need of medical care.10 
Impaired physical functioning and high fall risk may lead clinicians to be uncomfortable in 
prescribing anticoagulants for AF after stroke, despite the robust evidence supporting its use in 
the post-stroke population.11 The objectives of this study were to identify, among Veterans with 
stroke and AF, predictors of anticoagulation prescription at hospital discharge, particularly 
examining the role of physical functioning and fall risk.   
 
Methods 
Design 
 This was a secondary analysis of a retrospective cohort of Veterans admitted to 
Veterans Administration Medical Centers (VAMC) with ischemic stroke (Office of Quality and 
Performance Stroke Special Study (OQP)).12 We utilized these data to assess the association 
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between patient fall risk and physical functioning with anticoagulation medication prescription at 
time of hospital discharge.  
 
Study Population   
For the original OQP Stroke Special Project, a cohort of Veterans was assembled using 
administrative data to identify patients with ischemic stroke based on a high sensitivity algorithm 
using International Classification of Disease-9 codes. A sample of 5000 patients was obtained 
by including 100% of Veterans from small volume centers (≤55 patients) and a random sample 
of 80% of Veterans at high volume centers (>55 patients). Patients were excluded if admitted: 
for elective carotid endarterectomy; only for post-stroke rehabilitation; for a non-stroke condition 
when the ischemic stroke event occurred; or to a VAMC that did not use the VHA electronic 
medical record system. 
Data were obtained via electronic medical record abstraction. The data collection tool 
was designed and revised and pilot tested in collaboration with the senior chart reviewers over a 
period of several months. Whenever possible, data elements for this study were defined to be 
identical to items collected as part of the External Peer Review Program to ensure high quality 
of data collection (e.g., methods for collecting: demographics; medications; laboratory data; etc). 
Specific training for the record abstraction for this study was developed and implemented using 
successful approaches deployed in a prior retrospective cohort study and included training 
models specific to the unique data elements that were collected in this study (e.g., the 
retrospective NIH stroke scale [NIHSS]).  
For this analysis, we included (Figure 1) Veterans with stroke and AF (n=635) who: were 
classified as being eligible for anticoagulation prescription for AF at discharge (n=447), and who 
had a documented inpatient fall risk score (Morse Falls Scale, see below); the final sample was 
n=334.  
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Potential Predictors of Anticoagulation  
Patient level data obtained from medical record review included: demographics, medical 
comorbidities (including past medical history, the Charlson comorbidity index, as well as 
concomitant medical conditions present upon admission); stroke symptom characteristics; vital 
sign data; ambulation status (at hospital day 2 and at discharge); and discharge disposition 
(categorized as home or not home). Among the 307 abstracted data elements, 90% had an 
inter-observer agreement ≥70%.12, 13 
 
Fall Risk 
We used the Morse Falls Scale (Morse) to determine fall risk, commonly used for in-
hospital fall risk assessment.14-16 The Morse-score was abstracted as part of the medical record 
review. The Morse was part of the nursing admission assessment at the majority of VA hospitals 
and therefore was routinely collected for most patients. Therefore, missing Morse-scores were 
related to facility policies regarding nursing admission processes. The Morse includes the 
following domains: falls history; secondary diagnoses; ambulation aides; intravenous therapy; 
gait impairment; and mental status. We used the Morse score as a continuous variable in the 
analyses; higher scores represent higher fall risk; we also classified the Morse score into three 
categories: <25, low risk; 25-45, moderate risk; and >45 high risk.17  
 
Motor Function 
We used the reliable and valid motor component of the Functional Independence 
Measure (FIM) as a measure of motor functioning after stroke.18, 19 FIM-motor data were 
available for 271 of patients in this sample. Higher scores represent better functioning and 
greater independence.  
 
Stroke Severity 
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 We used valid and reliable retrospective National Institutes of Health Stroke Scale 
(NIHSS) to assess stroke severity.20, 21 The NIHSS is an 11-item scale and includes: 
consciousness; vision; language; sensory; ataxia; and arm and leg motor function. Increasing 
scores represent greater stroke severity.   
 
Thromboembolic Risk  
We calculated two scores for use in evaluating the anticoagulation management: the 
CHADS2 and the HAS-BLED.  
 
The CHADS2 score assesses the following domains: Congestive heart failure (1 point); 
Hypertension (1 point); Age >75 (1 point); Diabetes (1 point); and Stroke or TIA (2 points). The 
CHADS2 is a commonly used prediction rule for estimation of thromboembolic risk among 
patients with atrial-fibrillation.22, 23 A CHADS2 score of >2 indicates increased thromboembolic 
risk and such patients are recommended for consideration for anticoagulation.24 Because all of 
the patients in this study had a stroke, each had a score of at least two, and therefore were 
considered at moderate to high thromboembolic risk and anticoagulation would have been 
recommended for all such patients unless a contraindication existed (see below regarding 
contraindications).  
We also calculated a HAS-BLED score, a scale that rates bleeding risk;25 the HAS-BLED 
scoring includes a point for: Hypertension; Abnormal renal and liver function; Stroke; Bleeding; 
Labile INRs; Elderly age over 65; and Drugs or alcohol, including antiplatelet agents and 
nonsteroidal anti-inflammatory drugs. A HAS-BLED score ≥3 indicates a high risk of bleeding 
and anticoagulation is cautioned for such patients. Although the HAS-BLED score can range 
from zero to nine, the maximum score in this cohort was eight because we did not have data 
regarding concomitant alcohol and drug use.  
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Outcome Measure – Anticoagulation  
Veterans eligible for anticoagulation were identified via an algorithm similar to that which 
is used by the Joint Commission, developed to identify patients who were ideal candidates for 
antithrombotic therapy (yes or no). Patients were not considered appropriate for anticoagulation 
at discharge if they: had a code status of comfort-care only; were discharged to hospice care; 
were discharged to other inpatient care; left against medical advice; were discharged to a 
Critical Access Hospital; were expired; the patient refused anticoagulation; or if there was any 
documented contraindication to anticoagulation or reason for non-prescription of 
anticoagulation. Documentation of a contraindication for anticoagulation or other reason for a 
lack of anticoagulation was a specific item in the algorithm (yes or no ‘document a 
contraindication/reason for not prescribing an anticoagulant medication at discharge’, not 
applicable, or patient refusal). Examples of reasons for not prescribing antithrombotic therapy 
included but were not limited to: allergy to antithrombotic therapy; current aortic dissection; 
bleeding disorder; brain/CNS cancer; CVA/hemorrhage; extensive/metastatic cancer; 
hemorrhage, any type; intracranial surgery/biopsy; peptic ulcer, current; planned surgery within 
7 days of discharge; risk or bleeding, current; unrepaired intracranial aneurysm. Anticoagulation 
for AF included warfarin, low molecular weight heparin, alternative anticoagulants, or 
intravenous heparin. Inter-rater agreement for all of the variables related to anticoagulation at 
discharge was 89% or higher.  
 
Statistical Analysis  
 All analyses were completed using SAS statistical software (version 9.2© (Cary, NC). 
Stroke characteristics, demographics, fall risk, and physical functioning variables potentially 
influencing anticoagulation medication prescription were evaluated in bivariate tests using chi-
square, Fisher’s exact, one way analysis of variance, or the Wilcoxon rank-sum test.   
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To identify variables independently associated with anticoagulation, we constructed 
bivariate and multivariable logistic regression models estimated with generalized estimating 
equation methodology which allowed us to incorporate clustering of patients within hospitals. 
The outcome of interest was anticoagulation medication prescription at discharge. Independent 
variables were those statistically significant at <0.05 in the bivariate tests and factors identified 
via a priori clinical judgment (Morse; FIM-motor; day 2 ambulation; NIHSS; and discharge HAS-
BLED>3). An event-per-variable ratio of 10:1 was maintained in multivariable models.26, 27 The 
level of statistical significance was set at p<0.05.  No imputations were made for missing data.  
 
Results  
The baseline characteristics for the 334 subjects included in this analysis are presented 
in Table 1. The average age was 75 years (±10), 328 (98%) were male, and 239 (77%) were 
white.   
 At discharge, anticoagulation was prescribed for 235 (70%) of patients; 230 patients 
were prescribed warfarin, 28 patients were prescribed a non-warfarin anticoagulant medication, 
most commonly in combination with warfarin (e.g., 24 patients with low molecular weight 
heparin and warfarin).  A total of 98/334 (29%) patients were taking warfarin or a non-warfarin 
anticoagulant at hospital admission: 93/235 (40%) of patients discharged on any anticoagulant 
were taking an anticoagulant upon admission (Table 1). 
Patients not prescribed anticoagulation had decreased function as per the FIM-motor (42 
vs 53, p=0.003), had worse Morse-scores (59 vs 52, p=0.009), and were less likely to be 
ambulatory (day 2 of hospitalization 60% vs 74%, p=0.009 or discharge (69% vs 80%, p=0.020). 
Patients discharged without anticoagulation were at greater bleeding risk (HAS-BLED, 4 vs. 3, 
p<0.001; Table 1).  
We included NIHSS, FIM-motor, ambulation on day 2 of hospitalization, Morse-score, 
and HAS-BLED in the multivariable model. Only FIM-motor scores (adjusted OR=1.02, 95%CI 
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1.001 to 1.028, p=0.03) and HAS-BLED scores (adjusted OR=0.36, 95%CI 0.22 to 0.58), 
p<0.001) were significantly associated with anticoagulation prescription at discharge. All 
independent variables were centered at their means (FIM=51.8 and HAS-BLED=3.45). 
Therefore, for the FIM-motor, there was a 2% increase in the odds of being prescribed 
anticoagulation at discharge for every one unit of increase in FIM-motor greater than 51.8. The 
HAS-BLED had the largest effect; for every unit increase above the mean of 3.45 there was a 
64% reduction in the likelihood of receiving an anticoagulation prescription at discharge.  
 
Discussion 
 The efficacy of anticoagulation medication use in prevention of stroke and stroke related 
death has been well documented.28-33 However, due to concerns about intracranial hemorrhage 
and systemic bleeding, not all patients at risk for stroke with AF are prescribed anticoagulation 
medications.29 Clinicians likely consider post-stroke fall risk, motor functioning, stroke events, 
hypertension, and other variables when evaluating the benefit-to-risk ratio for individual patients.  
Overall, we found the majority (70%) of eligible patients with stroke and AF were 
prescribed anticoagulation at hospital discharge. This rate is somewhat lower than the 
anticoagulation rate observed in hospitals participating in the American Stroke Association Get 
With The Guidelines-Stroke program, where rates improved from 60% in 2003 to >90% by 
2009.34 It is expected that the rate would be somewhat lower in our sample, as it was not 
restricted to hospitals participating in stroke quality improvement programs.  
The 30% of eligible patients who were not prescribed an anticoagulant at discharge had 
worse FIM-motor scores, worse Morse-scores, and were less likely to be ambulatory on day 2 of 
the hospitalization or at discharge. Thus, patient physical functioning may be playing a key role 
in anticoagulation decision-making. Importantly, 70% of this study sample were receiving 
appropriate anticoagulation. The other 30% did not receive anticoagulation; however it may 
have been appropriate for these individuals to not receive anticoagulation, but there is a lack of 
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documentation regarding the decision-making. Our date does not include the actual 
documented contraindication, only ‘yes or no’, whether or not a contraindication was 
documented. It is unknown whether the contraindication would or would not be appropriate to 
withhold anticoagulation, thus the risk-to-benefit ratio of anticoagulation cannot be assessed. Of 
additional note, an important future area of quality improvement work should target the 
documentation of clinical decision-making relevant to anticoagulation.  
Our results indicate that only FIM-motor scores and the discharge HAS-BLED score 
were independent predictors of anticoagulation at post-stroke discharge. We hypothesized that 
fall risk would be predictive of anticoagulation prescription post-stroke, but our results did not 
support this hypothesis, at least independently. Our bivariate results demonstrated a significant 
difference in Morse-scores between those with and those without anticoagulation prescription; 
however the Morse was not maintained in the regression model. Additionally, it is of interest that 
stroke severity did not appear to influence anticoagulation decision-making in these patients, 
even though stroke risk is a primary indicator for anticoagulation.5  
The FIM-motor score was maintained in the model. Perhaps this is because the FIM-
motor score encompasses motor disability, including transfers, stairs, and locomotion, and thus 
fall risk is embedded. Similarly, although the NIHSS (a measure of stroke severity) was entered 
into the multivariable analysis, it was not retained in the final model; we hypothesize that the 
FIM-motor component accounted for disability related to neurological symptoms.  Therefore, 
while it seems that management of AF may improve functional recovery,35 physicians may be 
wary of prescribing or managing anticoagulation for someone with decreased motor ability.  
Interestingly, the HAS-BLED was maintained in the regression analyses, indicating 
bleeding risk is a predictor of anticoagulation for people with stroke and AF. The CHADS2 was 
likely not different between groups because all of the patients scored at least a 2 due to the 
stroke event for which they were admitted to the hospital. Those who did not receive 
anticoagulation had an average of a 4 on the HAS-BLED; as stated above, a score of >3 
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indicates a high risk for bleeding and such patients are not recommended for receipt of 
anticoagulation therapy. Our findings regarding the HAS-BLED are interesting when couched in 
a review of pertinent literature and AF guidelines. The HAS-BLED was recently found to better 
predict clinically relevant bleeding in people with AF when compared to two other assessments; 
however all three assessments only performed modestly in predicting bleeding risk.36 
Additionally, the guidelines distributed by the American College of Chest Physicians do not 
endorse the use of the HAS-BLED to assist in anticoagulation decision-making.37 Perhaps our 
finding that the HAS-BLED score was maintained in the predictive model is attributable to this 
being a study population including people with AF and stroke, the mentioned guidelines include 
people with AF, not necessarily with stroke. Perhaps an assessment of elevated bleeding risk 
explains why anticoagulation was not prescribed in this group of patients; however, no 
documentation about such a bleeding risk assessment was present in the inpatient medical 
record. Given the robust literature supporting the use of anticoagulation among the post-stroke 
population with AF, it is necessary to document reasons for not prescribing anti-coagulation 
medications at the time of hospital discharge.  
 
Limitations 
Limitations to this study include that all patients were Veterans (mostly men) cared for in 
VAMCs across the country; however, this does help us understand care within the single largest 
healthcare organization in the United States. Given that VHA uses an electronic medical record 
system but one that does not generally include decision support for AF patients, these results 
may not be generalizable to systems without electronic medical records or to settings with 
documentation reminders (or other decision support) related to anticoagulation decision-making 
or AF management. Finally, the VHA formulary during the study period did not include any of 
the new anticoagulant medications, and therefore these results pertain mainly to the use of 
warfarin. 
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Conclusion 
These data suggest that decisions regarding anti-coagulation for Veterans with stroke 
and AF appear to be made based on Veteran functional disability and bleeding risk. Thus it is 
likely that some patients are receiving the appropriate care but fail the anti-coagulation measure 
due to lack of documentation. Clinicians appear to be considering both bleeding risk and motor 
functioning when making anticoagulation decisions. Clinicians should strive to ensure that 
medical record documentation specifies reasons and clinical decision-making for non-
prescription of anticoagulation for post-stroke patients with AF whom they deem to be poor 
candidates for anticoagulation.  
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Table 1: Descriptive Statistics for Patients with Atrial Fibrillation and Morse Score by Anticoagulation Status  
Variable Overall  No 
Anticoagulation 
at Discharge 
Anticoagulation 
at Discharge 
 
p-value 
 (N=334) (N=99) (N=235)  
Age, in years (mean ± standard deviation) 75 ± 10   75 ± 10 74 ± 10 0.4402 
Sex, male 328 (98%) 97(98%) 231(98%) 0.9999 
White race/ethnicity 239 (77%) 67(68%)) 172(73%) 0.3076 
NIHSS Stroke severity 5 ± 6 5 ± 7 4 ± 6 0.0670 
FIM motor (last inpatient assessment) 50 ± 27  42± 26 53 ± 26 0.0027 
Charlson comorbidity score 2 ± 2  1 ± 2 1 ± 1 0.7144 
Comorbidities, past history of:     
Atrial Fibrillation 334 (100%) 99(100%) 235(100%)  
Hypertension 286 (86%) 88(89%) 198(84%) 0.2703 
Coronary Artery Disease 122 (36%) 33(33%) 89(38%) 0.4314 
Cerebrovascular Disease 107 (32%) 32(32%) 75(32%) 0.9418 
Ischemic Stroke 78 (23%) 22(22%) 56(24%) 0.7512 
Myocardial Infarction 46 (14%) 16(16%) 30(13%) 0.4109 
Transient Ischemic Attack 33 (10%) 11(11%) 22(9%) 0.6246 
Hemorrhagic stroke 10 (3%) 4(4%) 6(2%) 0.4904 
CEA/Stent procedure 10 (3%) 2(2%) 8(3%) 0.7292 
DVT/PE 6 (2%) 0(0%) 6(3%) 0.1849 
CHADS2 score at D/C (Mean ± SD) 4 ± 1 4 ± 1 4 ± 1 0.4387 
HAS-BLED score at D/C (Mean ± SD) 3 ± 1 4 ± 1 3 ± 1 <.0001 
Morse falls score 54 ± 25  59 ±  24 52 ± 25 0.0093 
Discharge disposition to home 190 (57%) 50(50%) 140 (60%) 0.1264 
Preadmission independent ambulation 311 (93%) 90(92%) 221(95%) 0.2227 
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Table 1: continued 
  
Variable Overall  No 
Anticoagulation 
at Discharge 
Anticoagulation 
at Discharge 
 
p-value 
 (N=334) (N=99) (N=235)  
 
Hospital Day 2 independent ambulation 227 (68%) 56(60%) 171(74%) 0.0084 
Discharge independent ambulation 257 (77%) 68(69%) 189(80%) 0.0200 
ADMISSION ANTITHROMBOTIC USE 
Any anti-thrombotic  98 (29%) 5 (5%) 93 (40%) <.0001 
    Non-Warfarin 1 (0.3%) 0 1 (0.43%) 0.7045 
    Warfarin 98 (29%) 5 (5%) 93 (40%) <.0001 
NIHSS=NIH Stroke Scale; FIM=Functional Independence Measure; DVT/PE=Deep vein thrombosis/Pulmonary embolism; CHADS2= Congestive 
heart failure, Hypertension,  Age >75, Diabetes, and Stroke or TIA; HAS-BLED=Hypertension, Abnormal renal and liver function, Stroke, Bleeding, 
Labile INRs, Elderly age over 65, and Drugs or alcohol 
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Table 2: Predictors of anticoagulation use at discharge, bivariate and multivariable odds ratios and 95% confidence intervals from 
logistic models with within hospital adjustment 
 Bivariate Results Multivariable Results 
 Estimate (SE) p-value Unadjusted 
Odds Ratios 
95% CI Estimate (SE) p-value Adjusted 
Odds Ratios 
95% CI 
Intercept     1.739 (0.393)    
NIHSS  -0.035 (0.019) 0.0672 0.965 (0.929, 1.003) 0.0008 (0.023) 0.9730 1.001 (0.956, 1.048) 
FIM motor  0.017 (0.005) 0.0004 1.017 (1.008, 1.027) 0.015 (0.007) 0.0329 1.015 (1.001, 1.028) 
HAS-BLED score  -0.768 (0.178) <.0001 0.464 (0.327, 0.657) -1.033 (0.251) <.0001 0.356 (0.218, 0.582) 
Morse falls score -0.014 (0.004) 0.0017 0.986 (0.978, 0.995) -0.006 (0.006) 0.3689 0.994 (0.982, 1.007) 
Hospital Day 2 
independent 
ambulation 
0.675 (0.256) 0.0085 1.963 (1.188, 3.245) 0.115 (0.395) 0.7709 1.122 (0.557, 2.433) 
NIHSS=NIH Stroke Scale; FIM=Functional Independence Measure; DVT/PE=Deep vein thrombosis/Pulmonary embolism; CHADS2= 
Congestive heart failure, Hypertension,  Age >75, Diabetes, and Stroke or TIA; HAS-BLED=Hypertension, Abnormal renal and liver 
function, Stroke, Bleeding, Labile INRs, Elderly age over 65, and Drugs or alcohol 
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List of abbreviations  
 
• Atrial fibrillation (A-fib) 
• Veterans Administration Medical Centers (VAMC)  
• Veteran Health Administration (VHA)  
• Office of Quality and Performance Stroke Special Study (OQP) 
• External Peer Review Program (EPRP) 
• National Institutes of Health Stroke Scale (NIHSS)  
• Functional Independence Measure (FIM) 
• Congestive heart failure; Hypertension; Age >75; Diabetes; and Stroke or TIA (CHADS2) 
• Hypertension; Abnormal renal and liver function; Stroke; Bleeding; Labile INRs; Elderly 
age over 65; and Drugs or alcohol (HAS-BLED) 
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Figure 1. Eligibility Flow Diagram 
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